Status:
UNKNOWN
Action of the Vidaza on the Atrial Fibrillation
Lead Sponsor:
Hospices Civils de Lyon
Conditions:
Atrial Fibrillation
Acute Leukemia
Eligibility:
All Genders
18+ years
Brief Summary
Genomic studies on atrial fibrillation patients have identified polymorphisms in regions surrounding the PITX2 gene, suggesting it could be the locus responsible for atrial fibrillation. The PITX2 gen...
Eligibility Criteria
Inclusion
- Age ≥ 18 years old
- Patient with history of paroxysmal atrial fibrillation, and /or presenting a dilatation of the left atrium.
- Patient selected for a first Vidaza® treatment
- Non-opposition of the patient to participate in the study
Exclusion
- Age \< 18 years old
- No paroxysmal atrial fibrillation
- Patients with previous history of Vidaza® treatment
Key Trial Info
Start Date :
December 20 2018
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 20 2021
Estimated Enrollment :
14 Patients enrolled
Trial Details
Trial ID
NCT03298321
Start Date
December 20 2018
End Date
December 20 2021
Last Update
October 16 2019
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Service de rythmologie - GH Est-Hôpital Louis Pradel - CHU de Lyon HCL
Bron, France, 69229
2
Centre Léon Berard
Lyon, France, 69008
3
Hopital Lyon Sud
Pierre-Bénite, France, 69310